en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
6/2021
vol. 59
 
Share:
Share:
more
 
 
abstract:
Letter to the Editor

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?

Dimitrios Ioannis Patoulias
1
,
Michael Doumas
1

1.
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece
Reumatologia 2021; 59, 6: 423–424
Online publish date: 2021/12/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Dear Editor,
Gout is the most common inflammatory arthritis in the United States, resulting from hyperuricaemia. The latter association represents an established risk factor for cardiovascular disease and coronary artery disease, as shown in a previous meta-analysis of observational studies in a total of 223,448 patients [1]. In addition, patients with gout due to uncontrolled hyperuricaemia experience an increased risk for non-fatal myocardial infarction (MI) [2], while they might also feature increased risk for stroke [3]. Recent real-world data also highlight the association between gout and atrial fibrillation, which inevitably augments the cardiovascular burden [4].
Allopurinol remains the uric acid-lowering treatment option of first choice, while febuxostat is prescribed when allopurinol is contraindicated or not tolerated [5]. Greater serum urate-lowering properties of febuxostat compared to placebo should be taken into account [6]. Unfortunately, medication adherence among gout patients is poor, associated with age and related co-morbidities [7].
Therefore, we sought to determine the comparative efficacy of febuxostat vs. allopurinol across surrogate cardiovascular outcomes of interest, by pooling data from the 2 dedicated cardiovascular outcome trials available so far [8, 9]. Our motive for this analysis was the U.S. Food and Drug Administration (FDA) warning raised after the publication of the CARES trial [8] regarding the increased risk for cardiovascular and all-cause death with febuxostat compared to allopurinol.
We assessed the following cardiovascular safety outcomes of interest: cardiovascular death, all-cause death, non-fatal MI, non-fatal stroke, fatal MI, fatal stroke, transient ischaemic attack, hospitalization for heart failure, coronary revascularization, cerebrovascular revascularization, and atrial fibrillation.
We assessed only dichotomous variables; therefore, we calculated the risk ratio with 95% confidence intervals, using an inverse variance-weighted random effects model. Statistical heterogeneity among studies was assessed by using I2 statistics. All analyses were performed at the 0.05 significance level, while they were undertaken with RevMan 5.3 software.
Our pooled analysis in a total of 12,318 patients with gout showed that subjects treated with febuxostat compared to those prescribed allopurinol did not experience an increased risk for any of the prespecified surrogate cardiovascular...


View full text...






Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.